197 related articles for article (PubMed ID: 6500405)
1. [Effects of ritodrine hydrochloride on motor nervous system and central nervous system].
Ikeda S; Tsukamoto T
Nihon Yakurigaku Zasshi; 1984 Sep; 84(3):311-26. PubMed ID: 6500405
[TBL] [Abstract][Full Text] [Related]
2. General pharmacological studies on N-(2,6-dimethylphenyl)-8-pyrrolizidineacetamide hydrochloride hemihydrate. 1st communication: effect on the central nervous system.
Hirotsu I; Kihara T; Nakamura S; Hattori Y; Hatta M; Kitakaze Y; Takahama K; Hashimoto Y; Miyata T; Ishihara T
Arzneimittelforschung; 1988 Oct; 38(10):1398-409. PubMed ID: 3196380
[TBL] [Abstract][Full Text] [Related]
3. [Effects of suloctidil on the central and peripheral nervous systems].
Nishi H; Watanabe T; Mori M
Nihon Yakurigaku Zasshi; 1983 Sep; 82(3):191-212. PubMed ID: 6319248
[TBL] [Abstract][Full Text] [Related]
4. General pharmacological properties of the new vasodilator flosequinan.
Ikezono K; Fujita S; Umezato M; Hosoki E; Toba Y; Kusunoki A; Shintani S
Arzneimittelforschung; 1992 Oct; 42(10):1200-11. PubMed ID: 1472141
[TBL] [Abstract][Full Text] [Related]
5. [Effects of a beta 2-stimulant, ritodrine hydrochloride, on the fetuses and dams in the late stage of pregnancy: an experimental study using rabbits].
Ikeda S; Nebashi Y; Akahane M
Nihon Sanka Fujinka Gakkai Zasshi; 1983 Nov; 35(11):1963-71. PubMed ID: 6663129
[TBL] [Abstract][Full Text] [Related]
6. General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjögren's syndrome. 1st communication: effects on general behavior and central nervous system.
Arisawa H; Imai E; Fujise N; Fukui K; Masunaga H
Arzneimittelforschung; 2002; 52(1):14-20. PubMed ID: 11838269
[TBL] [Abstract][Full Text] [Related]
7. General pharmacological properties of the main metabolite of flosequinan.
Fujita S; Ikezono K; Umezato M; Hosoki E; Toba Y; Ishikawa M; Kusunoki A; Shintani S
Arzneimittelforschung; 1992 Oct; 42(10):1212-22. PubMed ID: 1335257
[TBL] [Abstract][Full Text] [Related]
8. General pharmacology of recombinant human tumor necrosis factor. 2nd communication: effects on central nervous system functions.
Kurumiya S; Miura Y; Nakatsuji K; Dodo M; Hori M; Ito T
Arzneimittelforschung; 1990 Feb; 40(2 Pt 1):225-31. PubMed ID: 2334465
[TBL] [Abstract][Full Text] [Related]
9. [Pharmacological studies on oxatomide. (5). Effect on the central and peripheral nervous systems].
Ohmori K; Ishii H; Shuto K; Nakamizo N
Nihon Yakurigaku Zasshi; 1983 Mar; 81(3):245-66. PubMed ID: 6134657
[TBL] [Abstract][Full Text] [Related]
10. Effects of azelastine hydrochloride, a novel anti-allergic drug, on the central nervous system.
Kaneko T; Kitahara A; Ozaki S; Takizawa K; Yamatsu K
Arzneimittelforschung; 1981; 31(8):1206-12. PubMed ID: 6117290
[TBL] [Abstract][Full Text] [Related]
11. Effects of ritodrine hydrochloride, a beta 2-adrenoceptor stimulant, on uterine motilities in late pregnancy.
Ikeda S; Tamaoki H; Akahane M; Nebashi Y
Jpn J Pharmacol; 1984 Jul; 35(3):319-26. PubMed ID: 6482092
[TBL] [Abstract][Full Text] [Related]
12. General pharmacological properties of the human corticotropin-releasing hormone corticorelin (human).
Andoh K; Kimura T; Saeki I; Tabata R; Yamazaki S; Eguchi I; Hanazuka M; Horii D; Munt PL; Davis AS
Arzneimittelforschung; 1994 Jun; 44(6):715-26. PubMed ID: 8053970
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological studies with the alpha 2-adrenoceptor antagonist midaglizole. Part II: Central and peripheral nervous systems.
Hirohashi M; Takasuna K; Kasai Y; Usui C; Kojima H
Arzneimittelforschung; 1991 Jan; 41(1):19-24. PubMed ID: 1675569
[TBL] [Abstract][Full Text] [Related]
14. General pharmacological profile of the novel cholecystokinin-A antagonist loxiglumide.
Saito T; Ukai K; Masuda T; Nakagawa T; Kimura K; Fujii M; Wakatsuki K; Saeki M; Kasai H
Arzneimittelforschung; 1997 Dec; 47(12):1375-82. PubMed ID: 9450167
[TBL] [Abstract][Full Text] [Related]
15. [Pharmacological properties of procaterol, a newly synthetized, specific beta 2-adrenoceptor stimulant. Part I. Effects on the CNS (author's transl)].
Hashimoto K; Shintani S; Yamashita S; Tei S; Takai M; Tsutsui M; Kawamura K; Ohkawa T; Hiyama T; Yabuuchi Y
Nihon Yakurigaku Zasshi; 1979 Apr; 75(3):271-89. PubMed ID: 43821
[TBL] [Abstract][Full Text] [Related]
16. General pharmacological properties of cilostazol, a new antithrombotic drug. Part I: Effects on the central nervous system.
Shintani S; Toba Y; Suzuki S; Ninomiya S; Umezato M; Hiyama T
Arzneimittelforschung; 1985; 35(7A):1157-62. PubMed ID: 4074429
[TBL] [Abstract][Full Text] [Related]
17. Pharmacology of amezinium, a novel antihypotensive drug. VI. Effect on central nervous functions.
Teschendorf HJ; Kretzschmar R; Kreiskott H; Weifenbach H
Arzneimittelforschung; 1981; 31(9a):1580-8. PubMed ID: 7197973
[TBL] [Abstract][Full Text] [Related]
18. General pharmacology of the new antimuscarinic compound vamicamide.
Yamamoto T; Honbo T; Tokoro K; Kojimoto Y; Kodama R; Ohtsuka M; Shimomura K
Arzneimittelforschung; 1995 Dec; 45(12):1274-84. PubMed ID: 8595084
[TBL] [Abstract][Full Text] [Related]
19. General pharmacological properties of muroctasin.
Kojima H; Hirohashi M; Kasai Y; Takasuna K; Fukumoto C; Akashi A
Arzneimittelforschung; 1988 Jul; 38(7A):1002-9. PubMed ID: 3190791
[TBL] [Abstract][Full Text] [Related]
20. [Pharmacological studies of 4-ethoxy-2-methyl-5-morpholino-3(2H)-pyridazinone (M73101). (5) Action of M73101 on the central nervous system (author's transl)].
Sato M
Nihon Yakurigaku Zasshi; 1979 Oct; 75(7):695-706. PubMed ID: 575516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
